These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32617376)

  • 1. Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.
    Lodise TP; Colman S; Alexander E; Stein DS; Fitts D; Goldberg L; Schranz J
    Open Forum Infect Dis; 2020 Jun; 7(6):ofaa209. PubMed ID: 32617376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
    Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
    J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
    File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
    Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
    Alexander E; Goldberg L; Das AF; Moran GJ; Sandrock C; Gasink LB; Spera P; Sweeney C; Paukner S; Wicha WW; Gelone SP; Schranz J
    JAMA; 2019 Nov; 322(17):1661-1671. PubMed ID: 31560372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
    Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
    Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
    LoVecchio F; Schranz J; Alexander E; Mariano D; Meads A; Sandrock C; Moran GJ; Giordano PA
    J Emerg Med; 2021 Jun; 60(6):781-792. PubMed ID: 33731270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials.
    Paukner S; Mariano D; Das AF; Moran GJ; Sandrock C; Waites KB; File TM
    Antibiotics (Basel); 2021 Dec; 10(12):. PubMed ID: 34943700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
    Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.
    Lodise T; Colman S; Stein DS; Fitts D; Goldberg L; Alexander E; Scoble PJ; Schranz J
    Open Forum Infect Dis; 2020 May; 7(5):ofaa145. PubMed ID: 32462049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
    Tang HJ; Wang JH; Lai CC
    Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
    Watkins RR; File TM
    Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
    Chahine EB; Sucher AJ
    Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic.
    Covvey JR; Guarascio AJ
    J Intern Med; 2022 Jan; 291(1):51-63. PubMed ID: 34425035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
    Veve MP; Wagner JL
    Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
    Dillon C; Guarascio AJ; Covvey JR
    Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Lefamulin: If Not Now, When?
    Mercuro NJ; Veve MP
    Curr Infect Dis Rep; 2020; 22(9):25. PubMed ID: 32834786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin.
    Wang H; Charles CV
    Sr Care Pharm; 2020 Aug; 35(8):349-354. PubMed ID: 32718391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP).
    Horcajada JP; Salata RA; Álvarez-Sala R; Nitu FM; Lawrence L; Quintas M; Cheng CY; Cammarata S;
    Open Forum Infect Dis; 2020 Jan; 7(1):ofz514. PubMed ID: 31988972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.
    Sawicki GS; Wicha WW; Hiley TS; Close NC; Gelone SP; Guico-Pabia CJ
    Clin Ther; 2024 Feb; 46(2):96-103. PubMed ID: 38195348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.